D-Dimer Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Analyzers, and Reagents & Consumables) By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular, Coagulation (DIC), and Others), By Test Type (Clinical Laboratory Tests, and Point-of-Care Tests), By Method Type (Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, and Others), By End User (Hospitals, Academic & Research Institutes, Diagnostic Centers and Others), and Region

D-Dimer Testing Market size was valued at US$ 1.56 billion in 2023 and is poised to grow at a CAGR of 4.5% from 2024-2030. D-dimer testing is a blood test to diagnose deep vein thrombosis (DVT), disseminated intravascular coagulation (DIC), and deep vein thrombosis (DVT). These tests are used to detect the existence of D-dimer in the blood and find any blood clots in the body.

The increasing prevalence of venous thromboembolism (VTE) and other blood clot-related diseases, and the growing acceptance of automated point-of-care analyzers that reduce time, cost, and distance, and accelerate the medical decision-making process are some primary factors that can boost the market. Apart from this, awareness among the people about this product, and efforts of new laboratories and pathological labs to cut down the test cost and increase research in the production of novel aptamers also accelerate the market in the future. Another factor that drives the market is that new aptamer can substitute antibodies, which is an inexpensive and highly effective method.

Moreover, changing lifestyle which promotes the risk of lifestyle-related diseases such as cardiovascular disease, obesity, and diabetes, and growing research and development events can drive market growth. However, some factors such as the high purchasing cost of D-dimer testing instruments and lack of technical skills can restrain the growth of the market. Another factor that can hinder the growth of the market is the effect of heterophilic antibodies on the evaluation of the D-dimer levels in the blood. Moreover, the growing prevalence of high D-dimer levels in people due to the increase in the rate of diseases is expected to produce lucrative opportunities for the global market.  

Key Developments

• In June 2022, the LumiraDx D-dimer test was used in the point-of-care setting, to allow the experts to rule out VTE in symptomatic patients.
• In February 2019, radiometer Limited announced that its AQT90 FLEX analyzer has successfully detected D-dimer POCT in a lower limb DCT case.